Carles Escriu (@carlesescriu) 's Twitter Profile
Carles Escriu

@carlesescriu

Thoracic Medical Oncology Consultant at The Clatterbridge Cancer Centre

ID: 1452115411

linkhttp://linkd.in/12dfTYy calendar_today23-05-2013 17:45:23

225 Tweet

153 Followers

272 Following

The BMA (@thebma) 's Twitter Profile Photo

Rishi Sunak said today at #PMQs that rising NHS waiting lists is down to industrial action. Well how about the last 13 years of rising waiting lists?

Rishi Sunak said today at #PMQs that rising NHS waiting lists is down to industrial action.

Well how about the last 13 years of rising waiting lists?
Roshana 🦴 (@roshanamn) 's Twitter Profile Photo

The Consultants of Dorset hospital have written a letter to Steve Barclay They strike tomorrow This letter is incredible I challenge anyone to refute a single point in it Worth a read for you too Wes Streeting

The Consultants of Dorset hospital have written a letter to <a href="/SteveBarclay/">Steve Barclay</a> 

They strike tomorrow 

This letter is incredible

I challenge anyone to refute a single point in it 

Worth a read for you too <a href="/wesstreeting/">Wes Streeting</a>
The BMA (@thebma) 's Twitter Profile Photo

Around 1 in 3 UK medical students plans to leave the NHS within 2 years of graduating says BMJ. Dr Latifa warns: “It is not too late to fix [this increasingly untenable situation], but the power to do so rests with the Government.” bma.org.uk/bma-media-cent…

NHS Million (@nhsmillion) 's Twitter Profile Photo

We’re trying to get as many followers as Rishi Sunak so we can show the government just how many people are prepared to fight for the NHS and its staff. Please can you help by following us and retweeting this?

We’re trying to get as many followers as Rishi Sunak so we can show the government just how many people are prepared to fight for the NHS and its staff.

Please can you help by following us and retweeting this?
MEDSIR (@wearemedsir) 's Twitter Profile Photo

We proceed with the Brainstorming Session series. Next up is the session focusing on unmet needs and research ideas in Non-Small Cell Lung Cancer #NSCLC Dr. Antonio Calles 🫁🚭 Giuseppe Banna Alfredo Addeo MD Carles Escriu #MEDSIRBrainstormingSeries #LungCancer #ClinicalTrials #Innovation

We proceed with the Brainstorming Session series. Next up is the session focusing on unmet needs and research ideas in Non-Small Cell Lung Cancer #NSCLC

<a href="/Tony_Calles/">Dr. Antonio Calles 🫁🚭</a> <a href="/gbanna74/">Giuseppe Banna</a> <a href="/Alfdoc2/">Alfredo Addeo MD</a> <a href="/CarlesEscriu/">Carles Escriu</a>

#MEDSIRBrainstormingSeries #LungCancer #ClinicalTrials #Innovation
MEDSIR (@wearemedsir) 's Twitter Profile Photo

Finally, we turn our focus to the Brainstorming Session on unmet needs and research ideas in Mesothelioma. Dr. Antonio Calles 🫁🚭 Giuseppe Banna Alfredo Addeo MD Carles Escriu #MEDSIRBrainstormingSeries #LungCancer #ClinicalTrials #Innovation

Finally, we turn our focus to the Brainstorming Session on unmet needs and research ideas in Mesothelioma.

<a href="/Tony_Calles/">Dr. Antonio Calles 🫁🚭</a> <a href="/gbanna74/">Giuseppe Banna</a> <a href="/Alfdoc2/">Alfredo Addeo MD</a> <a href="/CarlesEscriu/">Carles Escriu</a> 

#MEDSIRBrainstormingSeries #LungCancer #ClinicalTrials #Innovation
MEDSIR (@wearemedsir) 's Twitter Profile Photo

Concluding the first #LungCancer #MEDSIRBrainstormingSeries! We delved into recent advancements and strategic development. Excited to lead in advancing knowledge and collaboration for the global benefit of cancer patients Dr. Antonio Calles 🫁🚭 Giuseppe Banna Alfredo Addeo MD Carles Escriu #Innovation

Concluding the first #LungCancer #MEDSIRBrainstormingSeries! We delved into recent advancements and strategic development. Excited to lead in advancing knowledge and collaboration for the global benefit of cancer patients
<a href="/Tony_Calles/">Dr. Antonio Calles 🫁🚭</a> <a href="/gbanna74/">Giuseppe Banna</a> <a href="/Alfdoc2/">Alfredo Addeo MD</a> <a href="/CarlesEscriu/">Carles Escriu</a>
 #Innovation
Lung Cancer Journal (@lungcajournal) 's Twitter Profile Photo

🚨📝 A pragmatic guide for management of adverse events associated with lorlatinib Link here 👉lungcancerjournal.info/article/S0169-… #LCSM ALK Positive

soria (@jsoriamd) 's Twitter Profile Photo

Lung cancer in never-smokers represent the 5thleading cause of cancer-related mortality in the world. They are highly enriched for targetable oncogenic alterations, have low TMB, low rates of PD-L1 positivity, & lack mutational signatures. They occur almost exclusively as

Lung cancer in never-smokers represent the 5thleading cause of cancer-related mortality in the world.  They are highly enriched for targetable oncogenic alterations, have low TMB, low rates of PD-L1 positivity, &amp; lack mutational signatures. They occur almost exclusively as
JAMA Oncology (@jamaonc) 's Twitter Profile Photo

Most cancer drugs granted accelerated approval did not demonstrate benefit in overall survival or quality of life within 5 years of accelerated approval. ja.ma/3J3zZMi #AACR24

Most cancer drugs granted accelerated approval did not demonstrate benefit in overall survival or quality of life within 5 years of accelerated approval. ja.ma/3J3zZMi #AACR24
Ben Solomon (@bensolomon1) 's Twitter Profile Photo

Alectinib in Resected ALK-Positive Non–Small-Cell Lung Cancer | New England Journal of Medicine nejm.org/doi/full/10.10…

Aɴᴛᴏɴɪᴏ Pᴀssᴀʀᴏ (@apassaromd) 's Twitter Profile Photo

🚀 Just out in Annals of Oncology: ETOP IBCSG Partners Foundation's position statement on antibody-drug conjugates (ADC) in lung and breast cancer. Honored to be a part of it, diving into the current evidence & future directions for clinical ADC development annalsofoncology.org/article/S0923-…

🚀 Just out in <a href="/Annals_Oncology/">Annals of Oncology</a>: <a href="/etop_ibcsg/">ETOP IBCSG Partners Foundation</a>'s position statement on antibody-drug conjugates (ADC) in lung and breast cancer. 
Honored to be a part of it, diving into the current evidence &amp; future directions for clinical ADC development 
annalsofoncology.org/article/S0923-…
Raffaele Colombo (@raffcolo) 's Twitter Profile Photo

Personal selection of 30 new (+ new-ish) ADCs that will be presented at #ASCO24 divided by payloads and targets. Notes: - Including "publication only" abstracts - Not including mainstream ADCs and/or combo - Not including trial in progress

Personal selection of 30 new (+ new-ish) ADCs that will be presented at #ASCO24 divided by payloads and targets. 

Notes:
- Including "publication only" abstracts
- Not including mainstream ADCs and/or combo
- Not including trial in progress
Brendon Stiles (@brendonstilesmd) 's Twitter Profile Photo

We’ll see how curves and TRAEs look, but in my opinion more evidence that we should be sprinting towards induction immunotherapy for patients w/ NSCLC treated with chemoradiation. Nitin Ohri @DrSteveMartin ascopubs.org/doi/abs/10.120…

Prof Lennart Nacke, PhD (@acagamic) 's Twitter Profile Photo

Abstracts are your paper's first impression. A weak abstract can sink even the best research. I transformed my abstract game with this 6-step Nature formula (and you can, too)

Abstracts are your paper's first impression.

A weak abstract can sink even the best research.

I transformed my abstract game with this 6-step Nature formula
(and you can, too)